Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy Dyne Therapeutics stock | $19.11
Learn how to easily invest in Dyne Therapeutics stock.
Dyne Therapeutics, Inc is an other business based in the US. Dyne Therapeutics shares (DYN) are listed on the NASDAQ and all prices are listed in US Dollars. Dyne Therapeutics employs 56 staff and has a market cap (total outstanding shares value) of 0.00.
How to buy shares in Dyne Therapeutics
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – DYN – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Dyne Therapeutics stock price (NASDAQ: DYN)Use our graph to track the performance of DYN stocks over time.
Dyne Therapeutics shares at a glance
|Latest market close||$19.11|
|52-week range||$13.50 - $32.32|
|50-day moving average||$20.52|
|200-day moving average||$19.09|
|Wall St. target price||$38.75|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.03|
Buy Dyne Therapeutics shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Dyne Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Dyne Therapeutics price performance over time
|1 week (2021-07-20)||N/A|
|1 month (2021-07-01)||-10.95%|
|3 months (2021-04-30)||-2.90%|
|6 months (2021-01-27)||N/A|
|1 year (2020-07-27)||N/A|
|2 years (2019-07-27)||N/A|
|3 years (2018-07-27)||N/A|
|5 years (2016-07-27)||N/A|
Is Dyne Therapeutics under- or over-valued?
Valuing Dyne Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Dyne Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Dyne Therapeutics's PEG ratio
Dyne Therapeutics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.19. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Dyne Therapeutics's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
However, it's sensible to consider Dyne Therapeutics's PEG ratio in relation to those of similar companies.
Dyne Therapeutics's EBITDA
Dyne Therapeutics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $753 million.
The EBITDA is a measure of a Dyne Therapeutics's overall financial performance and is widely used to measure a its profitability.
To put Dyne Therapeutics's EBITDA into context you can compare it against that of similar companies.
Dyne Therapeutics financials
|Gross profit TTM||$0|
|Return on assets TTM||-18.78%|
|Return on equity TTM||-31.09%|
|Market capitalisation||$914.5 million|
TTM: trailing 12 months
Shorting Dyne Therapeutics shares
There are currently 1.9 million Dyne Therapeutics shares held short by investors – that's known as Dyne Therapeutics's "short interest". This figure is 2.1% up from 1.8 million last month.
There are a few different ways that this level of interest in shorting Dyne Therapeutics shares can be evaluated.
Dyne Therapeutics's "short interest ratio" (SIR)
Dyne Therapeutics's "short interest ratio" (SIR) is the quantity of Dyne Therapeutics shares currently shorted divided by the average quantity of Dyne Therapeutics shares traded daily (recently around 303230.47001621). Dyne Therapeutics's SIR currently stands at 6.17. In other words for every 100,000 Dyne Therapeutics shares traded daily on the market, roughly 6170 shares are currently held short.
To gain some more context, you can compare Dyne Therapeutics's short interest ratio against those of similar companies.
However Dyne Therapeutics's short interest can also be evaluated against the total number of Dyne Therapeutics shares, or, against the total number of tradable Dyne Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Dyne Therapeutics's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Dyne Therapeutics shares in existence, roughly 40 shares are currently held short) or 0.0935% of the tradable shares (for every 100,000 tradable Dyne Therapeutics shares, roughly 94 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Dyne Therapeutics.
Find out more about how you can short Dyne Therapeutics stock.
Dyne Therapeutics share dividends
We're not expecting Dyne Therapeutics to pay a dividend over the next 12 months.
Dyne Therapeutics overview
Dyne Therapeutics, Inc. , a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was founded in 2017 and is headquartered in Waltham, Massachusetts. .
Stocks similar to Dyne Therapeutics
Dyne Therapeutics in the news
We Think Dyne Therapeutics (NASDAQ:DYN) Can Afford To Drive Business Growth
Dyne Therapeutics (DYN) Shares Cross Below 200 DMA
Frequently asked questionsWhat percentage of Dyne Therapeutics is owned by insiders or institutions?
Currently 2.895% of Dyne Therapeutics shares are held by insiders and 98.314% by institutions. How many people work for Dyne Therapeutics?
Latest data suggests 56 work at Dyne Therapeutics. When does the fiscal year end for Dyne Therapeutics?
Dyne Therapeutics's fiscal year ends in December. Where is Dyne Therapeutics based?
Dyne Therapeutics's address is: 830 Winter Street, Waltham, MA, United States, 02451 What is Dyne Therapeutics's ISIN number?
Dyne Therapeutics's international securities identification number is: US26818M1080 What is Dyne Therapeutics's CUSIP number?
Dyne Therapeutics's Committee on Uniform Securities Identification Procedures number is: 26817G300
More guides on Finder
How to buy Argus Capital Corp (ARGU) stock when it goes public
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
How to buy RenovoRx (RNXT) stock when it goes public
Everything we know about the RenovoRx IPO, plus information on how to buy in.
How to buy Draganfly (DPRO) stock when it goes public
Everything we know about the Draganfly IPO, plus information on how to buy in.
How to buy Society Pass Incorporated (SOPA) stock when it goes public
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
How to buy Guardforce AI Co (GFAI) stock when it goes public
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
How to buy IsoPlexis Corporation (ISO) stock when it goes public
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
How to buy Marpai (MRAI) stock when it goes public
Everything we know about the Marpai IPO, plus information on how to buy in.
How to buy DoubleDown Interactive (DDI) stock when it goes public
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
How to buy Omniq Corp (OMQS) stock when it goes public
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
How to buy Mechanical Technology (MKTYP) stock when it goes public
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
Ask an Expert